A prospective, randomized, multicenter study addressed the safety and efficacy of fluconazole therapy in 143 liver transplant patients. Seventy-six patients received daily oral fluconazole (100 mg), and 67 received nystatin (4 X 106 U) during the first 28 days after transplantation. Candida colonization occurred in 25 96 and 53 96 of patients in the fluconazole and nystatin groups, respectively (P sz .04), and 1396 and 3496 of patients in the respective groups had Candida infections (P = .022). Of these patients, 10.596 in the fluconazole group and 25.3 96 in the nystatin group had superficial candidal infections (P = .024). Invasive candidiasis developed in 2 patients in the fluconazole group (2.696) and 6 in the nystatin group (9.096) (P = .12). There was no increased hepatotoxicity, cyclosporine interaction, or emergence of clinically relevant resistant Candida strains attributable to fluconazole. Thus, oral fluconazole (100 mg) is safe and reduces Candida colonization and infection after liver transplantation. 
Infections remain a major cause of morbidity and mortality in solid-organ transplant recipients [1] [2] [3] , especially those caused by fungi, even though they are less frequent than bacterial and viral infections [1] [2] [3] [4] . Among solid-organ recipients, liver transplantation conveys the highest risk for fungal infections (10o7o-50o7o) and 50o7o-100o7o associated mortality [2, 5-9]. Candida species account for ^507o of fungal infections after liver transplantation and result in 25o7o-60o7o mortality [4] . Translocation of Candida in the endogenous gut flora across the intestinal mucosa and disruption of the biliary tract and small bowel during transplantation surgery have been implicated in the pathogenesis of this infection [5, 10, 11] . Bone marrow transplant recipients have a similar incidence of Candida infection and an associated mortality of 80o7o. Thus, major efforts have been made to reduce the incidence of fungal infection in bone marrow transplant recipients by use of prophylactic antifungal agents [12] [13] [14] . Because the pathogenesis and risk factors of bone marrow recipients differ from those of solidorgan transplant recipients, it is difficult to extrapolate prophylaxis regimens between the two types of transplants [4] .
Various antifungal prophylactic regimens have been studied in solid-organ recipients, including liver transplant patients.
Nystatin reduces oropharyngeal and rectal colonization with
Candida organisms, but data are lacking regarding its effectiveness in reducing deep fungal infection in liver recipients [15] . Oral azoles such as ketoconazole also reduce Candida colonization. However, because of potential hepatotoxicity and limitations in gastrointestinal absorption and interaction with cyclosporin A, this agent is a less than ideal prophylactic. Amphotericin B and its liposomal formulation are currently being evaluated, but the inconvenience and cost of parenteral administration plus side effects make its use cumbersome.
Fluconazole has several features that could make it useful as an anti-Candida agent after liver transplantation. It is potent to Candida, can be given orally, and is relatively safe at low doses [16] . However, because it potentially could interact with cyclosporin A and tacrolimus and may be hepatoxic, it needs to be carefully evaluated in liver transplant recipients. In addition, resistant Candida organisms are emerging. In recent studies in neutropenic leukemic patients and in bone marrow transplant recipients, oral fluconazole was safe and reduced colonization and invasive Candida infection [13, 14, 17] . Thus, on the basis of fluconazole's safety profile and its efficacy as a prophylactic agent in bone marrow transplantation, a randomized controlled study was undertaken in liver transplant recipients. The study determined fluconazole's potential hepatotoxicity and interaction with cyclosporin A and its usefulness as a prophylactic agent to reduce colonization and infection with Candida organisms.
Patients and Methods
Patient population. Eligible patients were liver transplant recipients ^ years old who had their first liver transplantation in the prior 24 h in one of three participant hospitals (Doce de Octubre, Puerta de Hierro, and La Paz). Patients were excluded if they had a history of hypersensitivity to azoles, had serum creatinine ^3 mg/dL, had received antifungal agents within 1 week of the study, or had evidence of a preexisting fungal infection. Patients who underwent retransplantation were also excluded from the study before randomization.
Study protocol. After screening, patients were randomly assigned to receive either 100 mg of fluconazole as a once-daily capsule or a nystatin suspension (106 U every 6 h) from days 3 to 28 after transplantation. Patients who required endotracheal intubation beyond day 3 received the drugs through nasogastric tubes. Randomization was done separately in each center in blocks of 10 patients each. Patients were clinically monitored for safety and for signs and symptoms of fungal infection within 24 h of transplantation, at study enrollment, weekly during the first 4 weeks after transplant, at week 8 and month 3, and when clinically indicated. Any posttransplant event was evaluated to determine drug-related complications or fungal infection.
Samples for mycologic cultures from the oropharynx, feces, and midstream urine were obtained at study enrollment and on days 7, 14, 21, and 28 after transplantation. Samples were cultured, and fungal elements were identified in Sabouraud agar for 48 h using conventional standardized clinical microbiology methods [18] . The same methodology was used in the three centers. In addition, samples from blood, other body fluids, and tissues were obtained as clinically indicated and cultured and analyzed for fungal infection as above. Serum creatinine, electrolytes, aspartate and alanine aminotransferases, alkaline phosphatase, total bilirubin, complete blood cell count and differential, and platelet counts were measured at least weekly during antifungal prophylaxis and at weeks 8 and 16. Cyclosporine levels were measured at least three times a week during antifungal prophylaxis. Decisions to administer empiric amphotericin B were made on a case-by-case basis by the individual investigator. All use of empiric antifungal therapy was recorded. Fluconazole dosage was reduced to 50 mg/day if creatinine clearance was ^0 mg/dL. If hemodialysis was required, 100 mg of fluconazole was administered orally after dialysis.
All patients were submitted to the same triple immunosuppression protocol?prednisone, azathioprine, and cyclosporine. Rejection episodes were treated with steroid boluses (1 g for 3 days) followed by OKT3 monoclonal antibody administration (5 mg/day for 10-14 days) if there was no response to steroid treatment. Perioperative antibacterial prophylaxis consisted of parenteral vancomycin and aztreonam during the first 24 h. Thereafter, oral prophylaxis with norfloxacin (400 mg/day) was administered for the first 4 weeks after transplantation.
Fungal colonization was defined as the isolation of fungal organisms from stool, throat, and urine cultures in the absence of clinical findings. Oropharyngeal candidiasis (thrush) was defined by the presence of oral lesions, odynophagia, and a positive culture for Candida in the absence of other pathogens. Candida cystitis was defined by dysuria, pyuria, and pure growth of Candida in the absence of a urinary catheter and, when a urinary catheter was in place, by the presence of dysuria, pyuria, and the isolation of a pure Candida growth at least twice (once after urinary catheter replacement). Invasive fungal infection was defined by the presence of organ-specific symptoms and evidence of Candida infection in blood, tissues, or bloody fluids. Esophageal candidiasis was identified by a compatible endoscopic appearance and a positive Candida culture from endoscopic biopsy specimens. Mortality. No significant difference in overall mortality was observed between the 2 groups up to 90 days after treatment. Among the fluconazole recipients, 10 (1307o) of 76 died as did 9 nystatin recipients (13 (7)). Of the deaths in the fluconazole group, 3 were associated with early development of multiorgan There were no differences in mean aminotransferase, alkaline phosphatase, and bilirubin levels at each biochemical evaluation between treatment groups. Moreover, no episode of liver dysfunction was attributed to drug toxicity.
Potential cyclosporine-fluconazole interactions were measured during study drug administration by comparing the mean cumulative dosage of cyclosporine required to maintain serum levels in the therapeutic range. No differences were found in the mean total dose of cyclosporine administered between the fluconazole and nystatin groups (8.2 ? 3.9 vs. 7.8 ? 2.9 g, respectively). As an indirect measure of cyclosporine-fluconazole interaction, no differences were found in the mean creatinine levels of both groups at each biochemical evaluation.
Discussion
Deep Candida infection remains a major problem in liver transplant recipients. Our study indicates that antifungal prophylaxis with fluconazole is safe and effective in preventing candidal infection in liver transplant recipients. Many liver transplant centers treat patients with nonabsorbable polyene compounds in an attempt to reduce Candida colonization within the endogenous flora of the gastrointestinal tract [4] . One advantage of fluconazole is that due to its favorable pharmacologic properties, it can reduce Candida colonization in locations other than the gut (e.g., urine, skin, and oral mucosa), sites in which yeast colonization correlates with the development of deep fungal infection in other immunosuppressed patients [19, 20] . Alternatives to oral absorbable agents include parenteral administered systemic agents (e.g., amphotericin). Some studies [21] but not others [22] have shown the efficacy of low-dose (10 mg/day) intravenous amphotericin B in preventing fungal infection. Nephrotoxicity, cyclosporine-amphotericin interactions, and myelotoxicity are major drawbacks to the generalized use of amphotericin B in solid-organ transplant recipients but may, in part, be overcome by use of liposomal amphotericin B [23] .
Our study indicates that oral fluconazole administered at low doses (100 mg/day) is a safe alternative for the prophylaxis of Candida infection in liver recipients. The greater efficacy of fluconazole than of nystatin in reducing the incidence of oral thrush may be due to its excellent oral absorption and penetration into saliva [24] . This may also pertain for the reduction of urinary colonization, ultimately influencing Candida cystitis. These findings may be relevant for other types of solid-organ transplant patients (e.g., renal system/pancreas) in whom urinary tract infections with Candida organisms are more frequent than in liver recipients [25] and in gut transplantation where systemic antifungal levels may be pertinent.
Invasive fungal (Candida) infection was lower in our study than in previous liver transplantation studies that reported 15oZo-20oZo infection rates [5, 7-10, 23, 26]. In our study, the incidence of deep fungal infection caused by Candida organisms was 8.9^0 in the nystatin group and 2.6^0 in the fluconazole group. This may in part be due to the short follow-up period (^3 months), when we would expect to observe an effect of an antifungal drug given during the first month after transplantation. Due to the low incidence of deep fungal infections in this early posttransplant period, it was not possible to determine statistical significance between groups. Thus, a larger sample will be required to confirm the trend towards a significant reduction of invasive Candida infection by fluconazole prophylaxis.
Only 2 cases of proven deep candidal infection occurred in the fluconazole group versus 6 (including the only case of disseminated candidiasis associated with death) in the nystatin group. Of interest, 3 episodes of deep Candida infection (1 in the fluconazole group, 2 in the nystatin group) developed after discontinuation of antifungal prophylaxis. The 3 patients shared several well-recognized risk factors for the development of fungal infections (surgical reinterventions, high doses of steroids for allograft rejection, and prolonged use of antibacterial antibiotics). This observation suggests that specific fungal prophylaxis should be given not only to patients with risk factors before and intratransplant (fulminant hepatitis, prolonged surgical intervention, or need for large volumes of blood product transfusions) but also to those who develop posttransplant risk factors. In the latter group, a more prolonged course with or without an increase in dosage should be considered. As expected, in our study there was less aspergillosis than candidal The potential for the selection or development of fluconazole-resistant Candida organisms, namely C. krusei and T. glabrata, needs to be considered. Wingard et al. [35] reported an increase of C. krusei colonization and infection when bone marrow transplant recipients were given 400 mg/day of fluconazole to prevent fungal infection. However, other studies in neutropenic leukemia and bone marrow transplant recipients did not find increased fluconazole-resistant yeasts during fluconazole prophylaxis, and even in those in whom there was an increased incidence of C krusei colonization, there was no associated significant morbidity or mortality [13, 14, 36] . In our study, in which we gave lower doses of fluconazole for a shorter period, no significant increase in the colonization and infection by fluconazole intrinsically resistant yeasts was observed except in 1 patient in the fluconazole group from whom T. glabrata was frequently isolated, although not leading to disease.
In conclusion, fluconazole prophylaxis was well tolerated and effective in preventing Candida infection in liver transplant recipients. A dose of 100 mg/day did not select for intrinsically resistant organisms, cause disease, or interact with cyclosporine. From the data derived from this study, it can be inferred that fluconazole should be a valid alternative agent in the prophylaxis of Candida infection after liver transplantation. It could be given immediately after transplant to persons with known pre-and intratransplant risk factors for development of Candida infections. In addition, occurrence of posttransplantation risk factors for C. albicans should trigger its use or prolong its administration.
